TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment of Stage IV Lip and Oral Cavity Cancer
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Randomized prospective trials have yet to demonstrate a benefit in either disease-free survival or overall survival for patients receiving neoadjuvant chemotherapy.[1] The use of isotretinoin daily for 1 year to prevent development of second upper aerodigestive tract primaries is under clinical evaluation.[2]
Continue within this section
Treatment Options for Advanced Lesions of the Lip →Treatment Options for Advanced Lesions of the Anterior Tongue →Treatment Options for Advanced Lesions of the Buccal Mucosa →Treatment Options for Advanced Lesions of the Floor of the Mouth →Treatment Options for Advanced Lesions of the Lower Gingiva →Treatment Options for Advanced Lesions of the Retromolar Trigone →Treatment Options for Advanced Lesions of the Upper Gingiva →Treatment Options for Advanced Lesions of the Hard Palate →Treatment Options Under Clinical Evaluation for All Stage IV Lip and Oral Cavity Cancers →
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice